BGM Group Ltd. has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited to acquire 100% of the equity interests of Wonder Dragon. This acquisition is valued at RMB550 million and is expected to be completed in the second quarter of 2025. The company’s CEO, Mr. Xin Chen, believes that the acquisition of Wonder Dragon will significantly advance the development of medicinal tea products and enhance the company’s position in the healthcare sector. By combining its biotechnology platform with the premium Qingzhuan dark tea resources of Wonder Dragon, BGM Group plans to introduce new health-focused tea products and accelerate the development of active ingredients for medicinal applications. Wonder Dragon holds a significant inventory of premium Qingzhuan dark tea, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. This valuable resource will provide a solid foundation for BGM Group’s research and development efforts. The acquisition strengthens BGM Group’s position in the healthcare sector by expanding its health product portfolio and market reach. The company has been at the forefront of integrating AI technology, big data analytics, and biopharmaceutical innovations to modernize traditional industries. Post-acquisition, BGM Group plans to optimize tea production efficiency, enhance product adaptability, and accelerate the development of active ingredients for medicinal applications. **Key Highlights of the Acquisition:**
* Acquisition of 100% of the equity interests of Wonder Dragon Global Limited
* Total transaction valuation of RMB550 million
* Expected completion date of second quarter of 2025
* Combination of biotechnology platform and premium Qingzhuan dark tea resources to enhance medicinal tea product development
* Introduction of new health-focused tea products and active ingredients for medicinal applications
The acquisition is expected to have a significant impact on BGM Group’s business operations and financial performance. The company’s focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals will be further enhanced through the acquisition. is a leading technology company that has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. The company’s biopharmaceutical division mainly produces oxytetracycline API, crude heparin sodium, and licorice preparations, which are widely supplied to the global animal husbandry, pharmaceutical, and drug retail markets. BGM Group’s Biopharmaceutical Division
The biopharmaceutical division of BGM Group Ltd. is capable of producing a range of biopharmaceutical products, including oxytetracycline API, crude heparin sodium, and licorice preparations. These products are widely supplied to the global animal husbandry, pharmaceutical, and drug retail markets.
| Biopharmaceutical Products | Production Capacity | Target Market |
|---|---|---|
| Oxytetracycline API | 500,000 kg/year | Global animal husbandry, pharmaceutical, and drug retail markets |
| Crude Heparin Sodium | 100,000 kg/year | Global pharmaceutical and drug retail markets |
| Licorice Preparations | 50,000 kg/year | Global pharmaceutical and drug retail markets |
Investor and Media Inquiries
For investor and media inquiries, please contact BGM Group Ltd. at info@qiliancorp.com. The acquisition of Wonder Dragon is a significant milestone in BGM Group’s business strategy. The company’s focus on integrating AI technology, big data analytics, and biopharmaceutical innovations will be further enhanced through the acquisition. With the premium Qingzhuan dark tea resources of Wonder Dragon, BGM Group is well-positioned to accelerate the development of medicinal tea products and enhance its position in the healthcare sector. The acquisition is expected to have a significant impact on BGM Group’s business operations and financial performance. Quoted Statement from Mr. Xin Chen, CEO of BGM Group
“Wonder Dragon’s Qingzhuan dark tea resources, combined with our biotechnology platform, will significantly advance our medicinal tea product development and distribution. By leveraging our technological expertise, we intend to introduce new health-focused tea products like ginseng Qingzhuan dark tea and goji berry Qingzhuan dark tea, further diversifying our’medicine + tea + health’ product ecosystem.”
In conclusion, the acquisition of Wonder Dragon is a significant milestone in BGM Group’s business strategy.
news is a contributor at Soozo. We are committed to providing well-researched, accurate, and valuable content to our readers.
